Inflammatory bowel disease increases the risk of hepatobiliary pancreatic cancer: A two‐sample Mendelian randomization analysis of European and East Asian populations
Cancer Medicine · 2023
DOI: 10.1002/cam4.6057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Jinsheng Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: VIP Department, Sun Yat-sen University Cancer Center, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Inflammatory Bowel Diseases, Liver Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Background
Both inflammatory bowel disease (IBD) and hepato‐pancreato‐biliary cancers (HPBC) have been established to cause a huge socioeconomic burden. Epidemiological studies have revealed a close association between IBD and HPBC.
Methods
Herein, we utilized inverse‐variance weighting to conduct a two‐sample Mendelian randomization analysis. We sought to investigate the link between various subtypes of IBD and HPBC. To ensure the accuracy and consistency of our findings, we conducted heterogeneity tests, gene pleiotropy tests, and sensitivity analyses.
Results
Compared to the general population, IBD patients in Europe exhibited a 1.22‐fold increased incidence of pancreatic cancer (PC) with a 95% confidence interval (CI) of 1.0022–1.4888 ( p = 0.0475). We also found a 1.14‐fold increased incidence of PC in Crohn's disease (CD) patients with (95% CI: 1.0017–1.3073, p = 0.0472). In the East Asian population, the incidence of hepatocellular carcinoma (HCC) was 1.28‐fold higher (95% CI = 1.0709–1.5244, p = 0.0065) in IBD patients than in the general population. Additionally, ulcerative colitis (UC) patients displayed 1.12‐fold (95% CI: 1.1466–1.3334, p < 0.0001) and 1.31‐fold (95% CI: 1.0983–1.5641, p = 0.0027) increased incidences of HCC and cholangiocarcinoma (CCA), respectively. Finally, the incidence of PC was 1.19‐fold higher in CD patients than in the general population (95% CI = 1.0741–1.3132, p = 0.0008).
Conclusion
Our study validated that IBD is a risk factor for HPBC. This causal relationship exhibited significant heterogeneity in different European and East Asian populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- VIP Department, Sun Yat-sen University Cancer Center, Guangzhou, China.
- State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Emergency, Shantou Central Hospital, Shantou, China.
ORCID-Profile: Lingli Huang, Guifang Guo
Förderung
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Huang, J., Li, X., Hong, J., Huang, L., Jiang, Q., Guo, S., Rong, Y., & Guo, G. (2023). Inflammatory bowel disease increases the risk of hepatobiliary pancreatic cancer: A two‐sample Mendelian randomization analysis of European and East Asian populations. Cancer Medicine. https://doi.org/10.1002/cam4.6057
Vancouver
Huang J, Li X, Hong J, Huang L, Jiang Q, Guo S, et al. Inflammatory bowel disease increases the risk of hepatobiliary pancreatic cancer: A two‐sample Mendelian randomization analysis of European and East Asian populations. Cancer Medicine. 2023. doi:10.1002/cam4.6057
BibTeX
@article{Huang2023,
author = {Huang, Jinsheng and Li, Xujia and Hong, Jicheng and Huang, Lingli and Jiang, Qi and Guo, Shunqi and Rong, Yuming and Guo, Guifang},
title = {Inflammatory bowel disease increases the risk of hepatobiliary pancreatic cancer: A two‐sample Mendelian randomization analysis of European and East Asian populations},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6057}
}
EUVIMED